Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: A double-blind, placebo-controlled trial

British Journal of Clinical Pharmacology

Volumn 42, Issue 4, 1996, Pages 415-421

  Davis, Timothy M E ^a   Dembo, Lawrence G ^a   Kaye Eddie, Sally A ^a   Hewitt, Benjamin J ^a   Hislop, Robert G ^a   Batty, Kevin T ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

glucose; insulin; mefloquine; neurological function; side effects

Indexed keywords

MEFLOQUINE; PLACEBO;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; FEMALE; HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; METABOLIC BALANCE; NEUROTOXICITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0029817206     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00003.x     Document Type: Article

References (30)

1. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44: 257-265.
2. Steffen R, Fuchs E, Schildknecht J, et al., Mefloquine compared with other chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341: 1299-1303.
3. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341: 848-851.
4. Van den Enden E, Van Gompel A, Colebunders R, van den Enden J. Mefloquine-induced Stevens-Johnson syndrome. Lancet 1991; 337: 683.
5. Martin GJ, Malone JL, Ross EV. Exfoliative dermatitis during malarial prophylaxis with mefloquine. Clin Infect Dis 1993; 16: 341-342.
6. Scerri L, Pace JL. Mefloquine-associated cutaneous vasculitis. Int J Dermatol 1993; 32: 517-518.
7. Hennequin C, Bouree P, Halfon P. Agranulocytosis during treatment with mefloquine. Lancet 1991; 337: 984.
8. Stracher AR, Stoeckle MY, Giordano MF. Aplastic anaemia during malarial prophylaxis with mefloquine. Clin Infect Dis 1994; 18: 263-264.
9. World Health Organisation. Prophylactic and therapeutic use of mefloquine. Weekly Epidemiologic Record 1989; 32: 247-248.
10. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side-effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45: 86-91.
11. Bjorkman A. Acute psychosis following mefloquine prophylaxis. Lancet 1989, ii: 865.
12. Bem JL, Kerr L, Sturchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95: 167-179.
13. Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 1989; 321: 1415-1416.
14. Lapras J, Vighetto A, Trillet M, Garin JP. Trouble transitoire de memoire au decours d'un acces palustre. Presse Med 1989; 18: 776.
15. Caillon E, Schmitt L, Moron P. Acute depressive symptoms after mefloquine treatment. Am J Psychiatry 1992; 149: 712.
16. Olson PE, Kennedy CA, Morte PD. Paresthesias and mefloquine prophylaxis. Ann Int Med 1992; 117: 1058-1059.
17. Rombo L, Angel VH, Friman G, Hellgren U, Mittelholzer ML, Sturchler D. Comparative tolerability and kinetics during long-term intake of Larium and Fansidar for malaria prophylaxis in nonimmune volunteers. Trop Med Parasitol 1993; 44: 254-256.
18. Rosenzweig P, Brohier S, Zipfel A. The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther 1993; 54: 578-583.
19. Smith A. Symbol digit modalities test manual. Western Psychological Services 1973.
20. Wechsler D. Manual for the Wechsler adult intelligence scale. New York, The Psychological Corporation 1955: 44.
21. Bergqvist Y, Hellgren U, Churchill F. High-performance liquid chromatography assay for the simultaneous monitoring of mefloquine and its acid metabolite in biological samples using protein precipitation and ion-pair extraction. J Chromatogr 1988; 432: 253-263.
22. Pennie RA, Koren G, Crevoisier C. Steady state pharmacokinetics of mefloquine in long-term travellers. Trans R Soc Trop Med Hyg 1993; 87: 459-462.
23. Mimica I, Fry W, Eckert G, Schwarz DE. Multiple dose kinetic study of mefloquine in healthy male volunteers. Chemotherapy 1983; 29: 184-187.
24. Davis TME, Karbwang J, Looareesuwan S, Turner RC, White NJ. Comparative effects of quinine and quinidine on glucose metabolism in normal man. Br J Clin Pharmacol 1990; 30: 397-403.
25. Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J 1986; 292: 1319-1321.
26. Assan R, Perronne C, Chotard L, Larger E, Vilde JL. Mefloquine-associated hypoglycaemia in a cachectic AIDS patient. Diabete Metab 1995; 21: 54-58.
27. Wittes R, Sanigur R. Adverse reaction to mefloquine associated with ethanol ingestion. Can Med Ass J 1995; 152: 515-517.
28. Lutman ME, Davis AC. The distribution of hearing threshold levels in the general population aged 18-30 years. Audiology 1994; 33: 327-350.
29. Roche RJ, Silamut K, Pukrittayakamee S, et al. Quinine induces reversible high-tone hearing loss. Br J Clin Pharmacol 1990; 29: 780-782.
30. Nosten F, Ter Kuile FO, Luxemberger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-1056.